What is the latest GLENMARK stock price?
The latest stored price for GLENMARK is Rs 2,293.00 as of 2026-10-09.
gimli
GLENMARK stock AI analysis
GLENMARK Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
GLENMARK PHARMACEUTICALS is a mid-cap stock in Healthcare. This Gimli page shows the latest available GLENMARK price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹2,293.00
1W return
-1.63%
1M return
-5.83%
3M return
+1.14%
6M return
+5.71%
1Y return
+18.46%
Market cap
₹64,708.64 cr
PE
35.99
PB
6.16
ROE
+18.57%
ROCE
+24.41%
RSI
44.30
Turnover
₹95.01 cr
Why it can matter in screens
- Momentum: GLENMARK is below 50DMA, above 200DMA; RSI is 44.30.
- Returns: 1D +4.60%, 1W -1.63%, 1M -5.83%, 3M +1.14%, 1Y +18.46%.
- Trend levels: 52W high ₹2,537.60, 52W low ₹2,101.00, off high -9.64%.
- Liquidity: latest turnover is ₹95.01 cr; volume vs 20D is +0.68%.
- Valuation/profitability: PE 35.99, PB 6.16, ROE +18.57%, ROCE +24.41%.
- Growth: 3Y sales CAGR +13.49%, 3Y profit CAGR +66.07%.
Quick Answers
Is GLENMARK above its 50DMA and 200DMA?
GLENMARK is below 50DMA, above 200DMA. The latest 50DMA is 2,360.58 and the latest 200DMA is 2,208.19.
What are GLENMARK PE, ROE and ROCE?
GLENMARK has PE 35.99, ROE +18.57%, and ROCE +24.41% in Gimli's latest available snapshot.
How has GLENMARK performed recently?
GLENMARK has returned -5.83% over 1 month, +1.14% over 3 months, and +18.46% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 3,931.73 cr | 870.56 cr | 482.92 cr | 17.11 |
| 2026-03-31 | 3,760.28 cr | 578.28 cr | 301.41 cr | 10.68 |
| 2025-12-31 | 3,888.00 cr | 729.88 cr | 403.21 cr | 14.29 |
| 2025-09-30 | 6,003.79 cr | 1,175.06 cr | 610.35 cr | 21.63 |
| 2025-06-30 | 3,059.33 cr | 283.73 cr | 46.87 cr | 1.66 |
| 2025-03-31 | 3,220.13 cr | 199.89 cr | 4.65 cr | 0.16 |
| 2024-12-31 | 3,301.90 cr | 631.36 cr | 347.96 cr | 12.33 |
| 2024-09-30 | 3,400.50 cr | 641.33 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 16,711.40 cr | 2,766.95 cr | 1,361.85 cr | 48.26 |
| 2025-03-31 | 13,145.84 cr | 2,092.28 cr | 1,047.10 cr | 37.11 |
| 2024-03-31 | 11,635.46 cr | 1,183.27 cr | -1,501.67 cr | -53.22 |
| 2023-03-31 | 11,431.94 cr | 1,200.15 cr | 297.25 cr | 10.53 |
| 2022-03-31 | 8,756.21 cr | 2,226.06 cr | 1,997.79 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 19,907.88 cr | 1,174.71 cr | 593.53 cr | 10,511.79 cr |
| 2025-03-31 | 16,049.55 cr | 1,675.71 cr | 2,472.67 cr | 8,849.07 cr |
| 2024-03-31 | 14,358.62 cr | 1,658.27 cr | 1,230.93 cr | 7,847.55 cr |
| 2023-03-31 | 19,371.68 cr | 1,159.20 cr | 4,607.88 cr | 9,839.26 cr |
| 2022-03-31 | 17,083.29 cr | 1,410.53 cr | 3,962.02 cr | 9,438.12 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3,445.03 cr | 2,087.32 cr | n/a |
| 2025-03-31 | -827.60 cr | -1,578.32 cr | n/a |
| 2024-03-31 | -265.44 cr | -1,163.82 cr | n/a |
| 2023-03-31 | 625.39 cr | 17.63 cr | n/a |
| 2022-03-31 | 1,108.65 cr | 318.54 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +46.65% | +20.89% | +18.60% | +16.76% | +13.81% | +0.00% |
| 2026-03-31 | +46.65% | +20.34% | +19.29% | +16.80% | +13.68% | +0.00% |
| 2025-12-31 | +46.65% | +19.20% | +20.09% | +17.86% | +14.02% | +0.00% |
| 2025-09-30 | +46.65% | +20.73% | +18.61% | +16.31% | +13.97% | +0.00% |
| 2025-06-30 | +46.65% | +20.62% | +17.64% | +15.55% | +15.06% | +0.00% |
| 2025-03-31 | +46.65% | +23.16% | +14.60% | +12.86% | +15.56% | +0.00% |
| 2024-12-31 | +46.65% | +23.51% | +13.85% | +12.12% | +15.96% | +0.00% |
| 2024-09-30 | +46.65% | +23.05% | +13.21% | +11.41% | +17.06% | +0.00% |
| 2024-06-30 | +46.65% | +20.98% | +13.92% | +10.92% | +18.41% | +0.00% |
| 2024-03-31 | +46.64% | +21.38% | +13.36% | +10.55% | +18.58% | +0.00% |
| 2023-12-31 | +46.65% | +23.71% | +10.92% | +8.59% | +18.69% | +0.00% |
| 2023-09-30 | +46.65% | +24.80% | +10.32% | +7.30% | +18.20% | +0.00% |
| 2023-06-30 | +46.65% | +25.52% | +9.11% | +5.36% | +18.68% | +0.00% |
| 2023-03-31 | +46.65% | +22.46% | +10.41% | +5.43% | +20.45% | +0.00% |
| 2022-12-31 | +46.65% | +23.20% | +10.69% | +5.64% | +19.43% | +0.00% |
| 2022-09-30 | +46.65% | +23.14% | +10.91% | +6.26% | +19.27% | +0.00% |
| 2022-06-30 | +46.65% | +0.00% | +34.73% | n/a | n/a | +0.00% |
| 2022-03-31 | +46.65% | +0.00% | +35.08% | n/a | n/a | +0.00% |
| 2021-12-31 | +46.65% | +0.00% | +35.04% | n/a | n/a | n/a |
| 2021-09-30 | +46.65% | +0.00% | +34.96% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| DIVISLAB | DIVI S LABORATORIES LTD | 247,947.67 cr | 85.088426 | +18.37% | +52.32% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
Try these prompts
- Analyze GLENMARK PHARMACEUTICALS with valuation, momentum and industry peers
- Compare GLENMARK with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare GLENMARK with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.